R&D channel feed

FDA asks for more da­ta from Opti­nose, ex­tends re­view time for nasal spray

Last year
FDA+

Sy­ros' stock up al­most 30% af­ter pos­i­tive ear­ly PhII da­ta for blood can­cer drug

Last year

Seagen po­si­tions Tukysa com­bo as op­tion for breast can­cer pa­tients with brain metas­tases

Last year

Ger­man biotech’s ef­forts to re­vive obe­si­ty tar­get for sol­id tu­mors yield pos­i­tive PhI­Ia re­sults

Last year

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

Last year
AI
In Focus

Phar­varis soars on mid-stage da­ta for se­vere swelling con­di­tion, rais­es $300M

Last year
Financing

IGM Bio­sciences cuts 22% of work­force, ax­es hema­to­log­ic on­col­o­gy pro­gram

Last year
People

Mer­ck KGaA’s evo­bru­ti­nib dis­ap­points in PhI­II mul­ti­ple scle­ro­sis test, cast­ing dark cloud over BTK class

Last year

J&J note­book: High­lights from a day of pipeline and strat­e­gy dis­cus­sion

Last year
Pharma

Bio­gen col­lab­o­ra­tor Neu­roSense shares sec­ondary PhI­Ib da­ta for its ALS treat­ment

Last year

Scoop: In­fec­tious dis­ease biotech eyes $25M Se­ries A to ad­vance an­ti­body for chron­ic lung in­fec­tion

Last year
Financing

Lil­ly’s Verzenio just miss­es the mark on over­all sur­vival in PhI­II breast can­cer study

Last year

J&J promis­es 20 new drugs to back phar­ma growth through end of decade, as John Reed shares his plans

Last year
Pharma

CRISPR repri­or­i­tizes CAR-T pipeline with cuts, ex­pands in­to au­toim­mune dis­ease as US de­ci­sion for exa-cel looms

Last year
Cell/Gene Tx

An­oth­er Flag­ship-found­ed biotech shut­ters as Ax­cel­la liq­ui­dates, end­ing long Covid plans

Last year
People

Al­to Neu­ro­science un­veils ef­fi­ca­cy sig­nal from PhI­Ia MDD tri­al with ma­chine learn­ing-iden­ti­fied bio­mark­er

Last year

Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

Last year

At­se­na touts one-year da­ta for con­gen­i­tal eye dis­ease ther­a­py as it seeks part­ner for piv­otal study

Last year
Cell/Gene Tx

UCSF sci­en­tists aim to un­rav­el autism with brain organoids and AI

Last year
AI

Seis­mic rais­es $121M to en­ter im­munol­o­gy space spot­light­ed by ar­genx, Im­muno­vant and oth­ers

Last year
Financing

Apel­lis' eye dis­ease drug gets safe­ty la­bel up­date for rare in­flam­ma­tion side ef­fect

Last year
FDA+

Up­dat­ed: Pfiz­er aban­dons twice-dai­ly GLP-1 ap­proach due to high dis­con­tin­u­a­tion rates, goes back to PhI with once-a-day dose

Last year

Al­tim­mune’s fate turns around af­ter longer look at obe­si­ty tri­al

Last year

Cy­bin gears up for reg­is­tra­tional tri­al of psilo­cy­bin ana­log in ma­jor de­pres­sion af­ter PhII suc­cess

Last year
First page Previous page 61626364656667 Next page Last page
A service from the Financial Times